Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 28, 2026Reported purchase · Form 4Stanley Frankel · $6.0KOpen the filing ↗
- Sep 25, 2026Reported purchase · Form 4Geno J Germano · $16.4KOpen the filing ↗
- Sep 25, 2026Reported purchase · Form 4Melinda Brown · $7.1KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record56919 flagged findings
Reported transactions (Form 4)80since Jun 2, 2025 · and 12 other holdings
Corporate events (8-K)30since Sep 27, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-08-06share offering or dilution eventfreshOpen filing ↗“…California (the “Cash Security Account”) at least equal to the outstanding principal amount of the 2024 Term Loan then outstanding.…”
+1 more passage from the same document
- “…agreement relating to a public offering of (i) 2,500,000 shares of the Company’s common stock, par value $ 0.000005 per…”
- 2026-08-06listing compliance noticefreshOpen filing ↗“…In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing…”
+1 more passage from the same document
- “…result in a delisting of our common stock. As previously disclosed, on April 24, 2023, we received a letter from Nasdaq (the “Nasdaq…”
- 2026-08-06regulatory investigationfreshOpen filing ↗“…• seize or detain products or otherwise require the withdrawal or recall of products from the market; • refuse to approve pending…”
- 2026-08-06reverse splitfreshOpen filing ↗“…requirements. As a result of the Approval and transfer to The Nasdaq Capital Market, we were granted an additional 180-day grace…”
+1 more passage from the same document
- “…to regain compliance with the Minimum Bid Price Requirement. On January 18, 2024, our stockholders approved a proposal to amend our…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
Reverse splits in 5 years
1 reverse split in 5 years (1:30 on Feb 14, 2024) · 1:30 cumulative
The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 569)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Aug 24, 26SCHEDULE 13G/A ↗Passive stake · Weinstein Benjamin · 4.0% · event on Aug 21, 26 · amendment
- Aug 24, 268-K ↗Current report · Communication to the market · Other events
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 29, 26SCHEDULE 13G/A ↗Passive stake · Empery Asset Management, LP · 5.0% · event on Jun 30, 26 · amendment
- Jul 27, 268-K ↗Current report · A senior executive left or was appointed
- Jul 20, 26SCHEDULE 13G ↗Passive stake · Lynx1 Capital Management LP · 5.4% · event on Jul 13, 26
- Jul 1, 268-K ↗Current report · Communication to the market · Other events
- Jun 16, 268-K ↗Current report · Entered a material agreement
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 5, 26Form 4 ↗Insider transaction
- Jun 5, 26Form 4 ↗Insider transaction
- Jun 5, 26Form 4 ↗Insider transaction
- Jun 5, 26Form 4 ↗Insider transaction
- Jun 5, 26Form 4 ↗Insider transaction
- Jun 3, 26Form 4 ↗Insider transaction
- Jun 3, 26Form 4 ↗Insider transaction
- Jun 3, 26Form 4 ↗Insider transaction
- Jun 3, 26Form 4 ↗Insider transaction
- May 27, 268-K ↗Current report · Communication to the market · Other events
569 filings on record, the oldest from Nov 16, 18.
Listing the 25 most recent filings of the 569 on record.
22425
- Jul 27, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 16, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 senior executive changes2024 – 2026show all 6hide
- May 26, 26A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Sep 2, 25A senior executive left or was appointed8-K 5.02 ↗
- Mar 7, 25A senior executive left or was appointed8-K 5.02 ↗
- Jan 29, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 12, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 10, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 16, 24A material agreement was terminated+3 more in the same filing8-K 1.02 ↗
- Jan 23, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 11, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Oct 25, 23Listing notice (8-K 3.01)8-K 3.01 ↗
- Oct 20, 23Entered a material agreement+1 more in the same filing8-K/A 1.01 ↗
- Oct 19, 23Entered a material agreement8-K 1.01 ↗
- Sep 7, 23A senior executive left or was appointed8-K 5.02 ↗
- Aug 16, 23Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Jul 6, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
8 older filings not shown · The record reaches back to May 20, 19.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Apr 28, 23Listing notice (8-K 3.01)8-K 3.01 ↗
The full record holds 2 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Octagon Capital Advisors LP10.0%Dec 31, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- Matthew Smith9.4%Jun 30, 25SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
- Aberdeen Group plc8.9%Dec 31, 25SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Bleichroeder LP8.2%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Lynx1 Capital Management LP5.4%Jul 13, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
show 3 more holdershide
- Empery Asset Management, LP5.0%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Weinstein Benjamin4.0%Aug 21, 26SCHEDULE 13G/A ↗
- Novartis Pharma AG3.7%Jun 30, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Sep 28, 26Buy$6KStanley Frankel↗
- Sep 25, 26Buy$16KGeno J Germano↗
- Sep 25, 26Buy$7KMelinda Brown↗
- Feb 18, 26Sell$19KJ. JEFFERSON SMITHChief Research Officer↗
- Feb 18, 26Sell$19KDario ScimecaGeneral Counsel and Secretary↗
- Feb 18, 26Sell$31KJohn Alexander KellyChief Financial Officer↗
- Feb 18, 26Sell$79KMichael AmorosoPresident and CEO↗
- Jan 22, 26Sell$145KMichael AmorosoPresident and CEO↗
- Jan 21, 26Sell$41KJ. JEFFERSON SMITHChief Research Officer↗
- Jan 21, 26Sell$61KJohn Alexander KellyChief Financial Officer↗
- Jan 21, 26Sell$36KDario ScimecaGeneral Counsel and Secretary↗
- Dec 16, 25Buy$13KStanley Frankel↗
There are 5 more transactions in this stretch.
Stock compensation, tax and giftsshow the 23 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- May 20, 26Compensationamount n/aGeno J Germano↗
- May 20, 26Compensationamount n/aShari Lisa Pire↗
- May 20, 26Compensationamount n/aMelinda Brown↗
- May 20, 26Compensationamount n/aStanley Frankel↗
- May 20, 26Compensationamount n/aKevin Buehler↗
- Feb 17, 26Compensationamount n/aJ. JEFFERSON SMITHChief Research Officer↗
- Feb 17, 26Compensationamount n/aDario ScimecaGeneral Counsel and Secretary↗
- Feb 17, 26Compensationamount n/aJohn Alexander KellyChief Financial Officer↗
- Feb 17, 26Compensationamount n/aMichael AmorosoPresident and CEO↗
- Jan 21, 26Compensationamount n/aJ. JEFFERSON SMITHChief Research Officer↗
- Jan 20, 26Compensationamount n/aJ. JEFFERSON SMITHChief Research Officer↗
- Jan 20, 26Compensationamount n/aJ. JEFFERSON SMITHChief Research Officer↗
- Jan 20, 26Compensationamount n/aJohn Alexander KellyChief Financial Officer↗
- Jan 20, 26Compensationamount n/aJohn Alexander KellyChief Financial Officer↗
- Jan 20, 26Compensationamount n/aJohn Alexander KellyChief Financial Officer↗
- Jan 20, 26Compensationamount n/aDario ScimecaGeneral Counsel and Secretary↗
- Jan 20, 26Compensationamount n/aDario ScimecaGeneral Counsel and Secretary↗
- Jan 20, 26Compensationamount n/aDario ScimecaGeneral Counsel and Secretary↗
- Jan 20, 26Compensationamount n/aMichael AmorosoPresident and CEO↗
- Jan 20, 26Compensationamount n/aMichael AmorosoPresident and CEO↗
- Jan 20, 26Compensationamount n/aMichael AmorosoPresident and CEO↗
- Nov 2, 25Compensationamount n/aMichael AmorosoPresident and CEO↗
- Nov 2, 25Compensationamount n/aDario ScimecaGeneral Counsel and Secretary↗
The full record holds 148 transactions and goes back to Jan 20, 23.
Its sector and its market
Precision Biosciences Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Precision Biosciences Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Precision Biosciences Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 569 documents on file, from Nov 16, 2018 to Sep 30, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.